Form 4: Biora Therapeutics Director Lynne Powell Reports Acquisition of Shares and Stock Options

Director Lynne Powell reports acquisition of 12,500 shares of common stock and 12,500 stock options in Biora Therapeutics.

Summary

• On June 5, 2024, Lynne Powell, a director of Biora Therapeutics, Inc., reported acquiring 12,500 shares of common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Powell directly owns 30,746 shares of common stock.
• Powell also acquired 12,500 stock options with an exercise price of $0.70.
• These options vest in full on the earlier of the first anniversary of the grant date or the date of the Issuer's 2025 annual meeting of stockholders, subject to continued service to the Issuer.
• The options expire on June 5, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction disclosure. The acquisition of shares and options by a director is generally viewed positively, but it's not a major event.

Positives

• A director's acquisition of shares and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon the Reporting Person's continued service to the Issuer.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, such as directors and officers, trade their company's stock. These filings provide transparency to the market and allow investors to track insider activity, which can sometimes provide insights into a company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

Biora Therapeutics, Lynne Powell, Director, Stock Options, Common Stock, Acquisition, Form 4, BIOR